MyFinsight
Home
Blog
About
Receivable from genevant
license
$179,373K
Investments in marketable
short-term securities
$73,454K
(21.06%↑ Y/Y)
Cash and cash
equivalents
$19,171K
(-48.76%↓ Y/Y)
Prepaid expenses and
other current assets
$1,516K
(-62.16%↓ Y/Y)
Accounts receivable
$369K
(-64.00%↓ Y/Y)
Total current assets
$273,883K
(165.60%↑ Y/Y)
Other non-current
assets
$132K
Property and equipment,
net of accumulated...
$10K
(-93.24%↓ Y/Y)
Total assets
$274,025K
(165.36%↑ Y/Y)
Total liabilities and
stockholders equity
$274,025K
(165.36%↑ Y/Y)
Total stockholders
equity
$258,733K
(211.82%↑ Y/Y)
Total liabilities
$15,292K
(-24.64%↓ Y/Y)
Deficit
-$1,215,521K
(11.18%↑ Y/Y)
Accumulated other
comprehensive loss
-$48,244K
(-0.12%↓ Y/Y)
Issued and outstanding
197,634,118 (december 31,...
$1,448,177K
(2.19%↑ Y/Y)
Contingent consideration
$8,817K
(-18.24%↓ Y/Y)
Total current
liabilities
$3,364K
(-33.01%↓ Y/Y)
Liability related to sale
of future...
$3,111K
(-20.43%↓ Y/Y)
Additional paid-in capital
$74,321K
(-10.05%↓ Y/Y)
Accounts payable and
accrued liabilities
$2,850K
(-36.78%↓ Y/Y)
Lease liability,
current
$514K
(0.00%↑ Y/Y)
Back
Back
Balance Sheet
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)
source: myfinsight.com